Below, we take a look at Madrigal (MDGL), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

Christmas is just around the corner, and with that comes the much anticipated 77th Annual Yuletide Madrigal Feaste. The ...

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...

Madrigal Pharmaceuticals' Rezdiffra for NASH shows strong early demand, positioning the company as a market leader. Read why ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

Yet another local race has gotten muddier, after an anonymous voicemail against one city council candidate surfaced Tuesday ...